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ABSTRACT 
Background: Genes regulated by breast cancer (BC) risk alleles identified through 
genome-wide association studies (GWAS) may harbour rare coding risk alleles.  
Methods: We sequenced the coding regions for 38 genes within 500kb of 38 lead 
GWAS SNPs in 13,538 breast cancer cases and 5,518 controls. 
Results: Truncating variants in these genes were rare, and were not associated with BC 
risk. Burden testing of rare missense variants highlighted five genes with some 
suggestion of an association with BC, though none met the multiple testing threshold: 
MKL1, FTO, NEK10, MDM4, and COX11. Six common alleles in COX11, MAP3K1 
(two), and NEK10 (three) were associated at the P<0.0001 significance level, but these 
likely reflect linkage disequilibrium with causal regulatory variants.  
Conclusions: There was no evidence that rare coding variants in these genes confer 
substantial breast cancer risks. However, more modest effect sizes could not be ruled 
out. 
Impact: We tested the hypothesis that rare variants in 38 genes near breast cancer 
GWAS loci may mediate risk. These variants do not appear to play a major role breast 
cancer heritability. 
  
 Genome-wide association studies (GWAS) have identified ~180 risk loci, (1) all of 
which are common variants that confer modest disease risks. Fine-mapping and 
functional analyses suggest that most causal variants modulate risk via regulatory 
effects, though a few lead SNPs, including in DCLRE1B and EXO1, are missense 
substitutions.(1) In some diseases, GWAS association signals have been shown to be 
mediated, at least in part, by rare, high-risk coding variants in nearby genes.(2) 
Moreover, even if GWAS signals are due to regulatory variants, rare coding variants in 
the target genes are biologically plausible candidates for modulating risk. In this study, 
we tested this hypothesis by sequencing the coding exons and intron-exon boundaries 
of 38 genes that are potential targets for GWAS-identified causal variants. 
 The subjects, DNA enrichment, sequencing, and variant calling employed in this 
study have been described elsewhere.(3) Sequencing primers, coverage statistics, 
quality metrics, and variants are in Tables S1-S4. 
 A total of 3,839 variants were identified, and most were rare, with 3,564 (92.8%) 
found in <0.1% of all sequenced subjects (non-coding variants) or ExAC European 
subjects (coding variants) (Figure S1, Tables S3-S4). Only 131 truncating variants 
were identified, and all were uncommon in the population (Tables S3-S4). Burden 
testing showed that truncating variants were not associated with risk for any gene, even 
at the nominal significance threshold (P<0.05; Table S5). 
 The aggregate of rare missense variants were not associated for any gene at 
P<0.0001; however, five genes were associated at P<0.05 (Figure 1, Table 1). 
Stratification with SIFT, PolyPhen2, and CADD effect predictions showed that only 
NEK10 variants with a CADD score >20 conferred a significantly higher risk than 
predicted benign variants (OR=2.73 and 0.86, respectively; P-diff=0.010) (Table S6). 
This signal was partially driven by variants within the highly conserved NEK10 protein 
kinase domain, which were more strongly associated than variants outside of the 
domain (Table 1; P-diff=0.033). In contrast, for MDM4, the association was stronger for 
variants outside Pfam-defined domains (Table 1). 
 Six common variants were associated with BC risk at P<0.0001 (Table S7), and 
all were in LD with the reported lead GWAS SNP: a 3’-UTR variant in COX11 
(rs1802212), two synonymous variants in MAP3K1 (p.Gln1028Gln, rs3822625; and 
p.Thr522Thr, rs2229882) and one missense and two synonymous variants in NEK10 
(p.Lys513Ser, rs10510592; p.Thr670Thr, rs11129280; and p.Thr687Thr,rs3213930). In 
each case the strength of the associations were compatible with those seen in 
Michailidou et al. (1), but the associations were much weaker than for the corresponding 
lead SNP (rs2787486, rs62355902 and rs4973769). 
 Among variants associated at P<0.05, DCLRE1B p.His49Tyr (rs11552449; 
OR=1.10) was also the lead GWAS SNP and conferred a similar risk to that seen in the 
initial study (OR=1.07, P=1.8x10-8).(4) 
 
Conclusion 
 Exon sequencing of genes in GWAS regions did not identify clear novel 
associations. There was no evidence for association with truncating variants in any 
genes, and while the variants were too rare to establish reliable estimates, these are 
unlikely to be large contributors to BC risk. There was limited evidence of association for 
rare missense variants in five genes, while 1.9 genes would have been expected to be 
associated by chance. Larger targeted studies will be required to establish whether any 
of these associations can be confirmed; if so, these may indicate novel associations 
distinct from the common variant associations identified through GWAS. 
 Six common variants were associated with BC after correcting for multiple 
testing, but all were in LD with the lead GWAS SNP, and therefore probably do not 
represent novel risk loci. Moreover, other non-coding SNPs in these regions were more 
strongly associated, suggesting that these associations are “passenger” associations 
reflecting LD with causal regulatory variants.(5)  
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Table 1.  Risk estimates for all rare missense variants in the 38 GWAS genes, as well as 
subsets of variants that are either localized within or outside of Pfam domain regions. 
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Figure 1. Variant position and frequency for rare missense variants in (A) MKL1; (B) 
FTO; (C) NEK10; (D) MDM4; and (E) COX11. Variants are color-coded by CADD 
prediction. ZnF=Zinc Finger Domain; SAP=Putative DNA/RNA binding domain. 
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Figure S1.
Figure S1. Spectrum of variation in the 38 BC GWAS genes from Experiment 2. (A) The total variant 
burden varied significantly from gene to gene. More than half of all variants were singletons, and 
few variants were found in more than three subjects. (B) The rates of total, novel, and truncating 
variants were more similar after correcting for gene length, but some genes had higher or lower 
variant rates per kb. (C) The contribution of each variant type was similar from gene to gene, though 
some genes had a higher contribution from truncating variants. EGOT is a long, non-coding RNA and 
therefore variants in that gene all fall into the “Other” category, which is otherwise largely 
comprised of UTR and non-canonical splice variants. While they were very rare, start lost, stop lost, 
and stop retained variants were also included in this category.
